Corcept Therapeutics Inc. (CORT)

PHARMACEUTICAL PREPARATIONS

Headquarters
United States
Employees
730
Market Cap
$12.8B

About Corcept Therapeutics Inc.

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

SentiSense also tracks daily options readings for Corcept Therapeutics Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

Corcept Therapeutics Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.